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I. INTRODUCTION
Tobacco litigation has seized national headlines for the latter half of
this decade. Battles over the power to regulate tobacco, however, have
waged for the past half century. This Case Note examines the quest for
regulatory control over tobacco within the context of Brown & Williamson
Tobacco Corp. v. DA. A review of this challenge to the Food and Drug
Administration's authority illustrates that interpretations of legislative his-
tory and standards of review serve as guideposts in the judicial assignment
of this increasingly important power.
A. The Tobacco Regulations
On August 28, 1996, as several states prepared lawsuits against the
tobacco companies,' the Food and Drug Administration ("FDA") made its
* The author would like to thank Professor Neil Hamilton, Trustees Profes-
sor of Regulatory Policy, William Mitchell College of Law, for his assistance with
this article.
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first attempt to regulate tobacco and limit its impact on public health.
The FDA has promulgated a number of regulations concerning the adver-
tising and sale of tobacco products. The regulations restrict sales to mi-
nors,3 require certain labeling on packages, 4 and impose limitations on
advertising.5 The advertising restrictions-which limit most ads to a black-
1. See, e.g., David Phelps, Blue Cross Given Green Light, STAR TRIB. (Minneapo-
lis-St. Paul),July 26, 1996, at ID; David Phelps, The Tobacco Fight, STAR TRIB. (Min-
neapolis-St. Paul), Oct. 21, 1996, at IA (explaining that seventeen states had filed
suit against the tobacco companies).
2. See Regulations Restricting the Sale and Distribution of Cigarettes and
Smokeless Tobacco to Protect Children and Adolescents, 61 Fed. Reg. 44,396
(1996) (to be codified at 21 C.F.R. pts. 801, 803, 804, 807, 820, and 897). The
agency explained:
Tobacco use is the single leading cause of preventable death in the
United States. More than 400,000 people die each year from tobacco-re-
lated illnesses, such as cancer, respiratory illnesses, and heart disease, of-
ten suffering long and painful deaths. Tobacco alone kills more people
each year in the United States than acquired immunodeficiency syn-
drome (AIDS), car accidents, alcohol, homicides, illegal drugs, suicides,
and fires, combined.
Id. at 44,398.
3. See 21 C.F.R. § 897.14 (1998). 21 C.F.R. § 897.14 prohibits retailers from
selling tobacco products to a person younger than eighteen years of age and re-
quires asking a purchaser twenty-six years old or younger for identification. See id.
Vending machines are prohibited unless located in an area closed to minors. See
21 C.F.R. § 897.16 (1998). Minnesota state law also prohibits sale to minors. See
MNN. STAT. § 609.685 (1998) (making sale of tobacco to minors a gross misde-
meanor).
4. See 21 C.F.R. § 897.24-.25 (1998). Tobacco packages must include a de-
scription of the product--such as "cigarettes"-and the label "Nicotine-Delivery
Device for Persons 18 or Older." Id.
5. See 21 C.F.R. § 897.30 (1998). The advertising restrictions are by far the
most restrictive. The regulations prohibit tobacco companies from advertising
within one thousand feet of a playground or elementary or secondary school. See
id. Advertising and labeling of tobacco products is limited to black text on a white
background, except in areas closed to minors and in adult publications. See 21
C.F.R. § 897.32 (1996). Advertising involving audio (such as radio ads) may not
include music or sound effects. See id. In addition, tobacco companies may not
sell products other than tobacco labeled with the brand name or other identifica-
tion of a tobacco product, give bonuses for the purchase of tobacco, or advertise at
athletic or cultural events using the brand name or identification of a tobacco
product. See 21 C.F.R. § 897.34 (1996). Interestingly, Congress has considered
bills which would prohibit tobacco companies from using other than black-and-
white text format advertisements, advertising within one thousand yards of a
school, sponsoring sports activities, or distributing samples. See Angela Turriciano,
The IDA Sends Smoke Signals to Big Tobacco: Will the FDA Suffer Backlash, Will Alcohol
Be Regulated Next, and Will the Health of Americans Prevail?, 25 PEPP. L. REv. 617, 623
(1998). These bills were not enacted. See id.
[Vol. 25
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and white format and prohibit sponsorship of any athletic or cultural
event using a tobacco brand name-have a serious impact on the indus-
try.6 The FDA focused on preventing use by minors, explaining that most
smokers begin to use tobacco at this critical age.7
When several tobacco companies, convenience store owners, and ad-
vertising agencies challenged the FDA's rule, a U.S. district court in North
Carolina held that the FDA had the authority to regulate tobacco products
under the Federal Food, Drug, and Cosmetics Act ("FDCA") 8 as combina-
tion devices. 9 On appeal, the Court of Appeals for the Fourth Circuit re-
versed in Brown & Williamson Tobacco Corp. v. Food & Drug Administration.10
This note addresses whether the FDA has the authority to regulate
tobacco products. It discusses the agency's change in position, subse-
quent legislative history, and the impact of these issues on the scope of re-
view. It concludes that the Fourth Circuit improperly relied on bills that
were not enacted and tobacco legislation enacted after the FDCA-subse-
quent legislative history-as a basis for its decision.
6. See Turriciano, supra note 5, at 630-31.
7. See Regulations Restricting the Sale and Distribution of Cigarettes and
Smokeless Tobacco to Protect Children and Adolescents, 61 Fed. Reg. 44,396,
44,397 (1996) (to be codified at 21 C.F.R. pts. 801, 803, 804, 807, 820, and 897).
According to studies cited by the FDA, 82% of current and former adult smokers
first smoked before age 18. See id. at 44,574. Most adults who smoke became regu-
lar smokers before age 18. See id. The FDA noted:
As long as children and adolescents become addicted to cigarette and
smokeless tobacco use in these numbers, there is little chance that society
will be able [to] reduce the toll of tobacco-related illnesses. If, however,
the number of children and adolescents who begin tobacco use can be
substantially diminished, tobacco-related illness can be correspondingly
reduced because data suggest that anyone who does not begin smoking
in childhood or adolescence is unlikely to ever begin .... Thus, the ap-
propriate emphasis is on reducing the use of tobacco products by chil-
dren and adolescents.
Id. at 44,399.
8. Act of 1938, ch. 675, 52 Stat. 140 (1938) (codified as amended at 21
U.S.C. §§ 301-394 (1994)).
9. See Coyne Beahm, Inc. v. FDA, 966 F. Supp. 1374, 1397 (M.D.N.C. 1997),
rev'd sub nom. Brown & Williamson Tobacco Corp. v. FDA, 153 F.3d 155 (4th Cir.
1998), and petition for cert. filed, 67 U.S.L.W. 3484 (U.S. Jan. 19, 1999) (No. 98-
1152). The case did, however, take most of the sting out of the regulations by
striking the advertising restrictions as outside of the FDA's authority. See id. at
1399-1400.
10. 153 F.3d 155 (4th Cir. 1998).
1999]
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B. The FDA's Analysis of the FDCA
The FDA made extensive findings in support of tobacco regulations.
The agency asserted jurisdiction over tobacco as a combination device."
The FDCA defines "drug" as:
(A) articles recognized in the official United States Pharmaco-
poeia...; and (B) articles intended for use in the diagnosis,
cure, mitigation, treatment, or prevention of disease in man or
other animals; and (C) articles (other than food) intended to
affect the structure .or any function of the body of man or other
animals .... 12
A "device" under the FDCA is an:
instrument, apparatus, implement, machine ... which is recog-
nized in the official National Formulary...
(2) intended for use in the diagnosis of disease or other condi-
tions, or in the cure, mitigation, treatment, or prevention of
disease, in man or other animals, or
intended to affect the structure or any function of the body of
man or other animals, and
which does not achieve its primary intended purposes through
chemical action within or on the body of man or other animals
and which is not dependent upon being metabolized for the
achievement of its primary intended purposes."
The FDA found cigarettes and smokeless tobacco to be combination
drug/device products because they include both nicotine and a delivery
system. 4 Further, they are "intended to affect the structure or any func-
tion of the body." 5
The Safe Medical Devices Act of 1976 gives the FDA the authority to
regulate combination drug/device products. 1 This amendment to the
11. 61 Fed. Reg. at 44,396 (1996).
12. 21 U.S.C. § 321(g) (1) (1994).
13. Id. § 321(h).
14. For a detailed explanation of the FDA's regulations, see Regulations Re-
stricting the Sale and Distribution of Cigarettes and Smokeless Tobacco to Protect
Children and Adolescents, 61 Fed. Reg. 44,396, 44,403 (1996) (to be codified at 21
C.F.R. pts. 801, 803, 804, 807, 820, and 897).
15. 21 U.S.C. § 321(h) (1994).
16. See id. § 353(g)(1); see also 61 Fed. Reg. at 44,400 (1996).
[Vol. 25
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FDCA states that the FDA "shall determine the primary mode of action of the
combination product" and regulate accordingly.17 The FDA made its de-
termination based not on how tobacco functions as a combination prod-
uct but rather on which classification-drug or device-provided it with
the most authority over tobacco. The agency explained:
Because of this additional flexibility [of the device provisions],
the agency has determined that the device authorities provide
the most appropriate basis for regulating cigarettes and smoke-
less tobacco. Because millions of Americans are addicted to
cigarettes and smokeless tobacco, regulation of these products
presents unique safety problems that require careful, tailored
solutions. The Medical Device Amendments provide the agency
with regulatory options that are well suited to the unique prob-
lems presented by cigarettes and smokeless tobacco. 8
This determination has significance because, although the FDA
found otherwise,' 9 the agency may not have been able to regulate tobacco
under the drug provisions of the FDCA. The FDCA defines a "new drug"
as:
[A] ny drug.., not generally recognized... as safe and effective
for use.0
To market a "new drug," a manufacturer must submit an ap-
plication to the FDA including full reports of investigations
which have been made to show whether or not such drug is safe
21for use and whether such drug is effective in use.
The FDA's next bit of creativity involved the classification of tobacco
as a type of device. The applicable statute divides devices into three
classes. The agency regulates Class I devices using "general controls" un-
der the Act; Class II devices require additional "special controls" such as
17. 21 U.S.C. § 353(g)(1) (emphasis added).
18. 61 Fed. Reg. at 44,404; see also Brown & Williamson Tobacco Corp. v.
FDA, 153 F.3d 155, 165 (4th Cir. 1998) (describing the agency's determination as
"obvious sophistry").
19. Not directly addressing premarket approval, the FDA stated that the drug
provisions allow it to "regulate these combination products." 61 Fed. Reg. at
44,414.
20. 21 U.S.C. § 321 (p) (1) (1994).
21. Id. § 355(b).
1999]
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performance standards; Class III devices require premarket approval." A
device has Class III status if Class I and II controls would not "provide rea-
sonable assurance of [its] safety and effectiveness" and its use "presents a
potential unreasonable risk of illness or injury."23 Premarket approval re-
quires "reasonable assurance of its safety and effectiveness. "24 The FDA
avoided a classification dilemma by choosing not to classify tobacco and by
regulating it under the general device controls."
These and other arguments led to the FDA's district court victory.
26
C. The Fourth Circuit's Opinion
The Fourth Circuit reversed the district court's holding and held that
the FDA does not have jurisdiction over tobacco. 7 The court did not de-
fer to the agency's interpretation of the Federal Food, Drug, and Cosmet-
ics Act because it found the statute unambiguous8 under the standard of
review articulated in the controlling case of Chevron U.S.A., Inc. v. Natural
Resources Defense Counsel, Inc." By promulgating the rule discussed above,
the Fourth Circuit determined that the FDA acted outside the "bounds of
its congressionally-established authority."3°
In reaching this conclusion, the court examined the plain language
22. See id. § 360c(a) (1).
23. Id.
24. Id.
25. See 61 Fed. Reg. at 44,396-404; see also Brown & Williamson Tobacco
Corp. v. FDA, 153 F.3d 155, 176 (4th Cir. 1998). The Fourth Circuit noted that
the FDA would not be able to approve tobacco products as a drug because the
FDA admits they are unsafe. See id. at 165. The Fourth Circuit was unimpressed
with the FDA's attempt to avoid obvious difficulties with premarket approval by
relying upon the device provisions of the Act. See id. The Commissioner of the
FDA had stated in congressional hearings that "if cigarettes were to be classified as
drugs, they would have to be removed from the market because it would be impos-
sible to prove they were safe for their intended [use]." Id. at 168. The agency's
justification for not completely banning tobacco due to its documented effect on
public health illustrates the tension in its position. See 61 Fed. Reg. at 44,398. The
FDA cited addicted users and the possibility of a black market in sidestepping the
basic issue of safety. See id.
26. See Coyne Beahm, Inc. v. FDA, 966 F. Supp. 1374, 1397 (M.D.N.C. 1997),
rev'd sub nom. Brown & Williamson Tobacco Corp. v. FDA, 153 F.3d 155 (4th Cir.
1998), and petition for cert. filed 67 U.S.L.W. 3484 (U.S. Jan 19, 1999) (No. 98-1152).
27. See Brown & Williamson, 153 F.3d at 176.
28. See id. at 161.
29. 467 U.S. 837 (1984). See infra notes 136-39 and accompanying text. The
Fourth Circuit based its decision on the first step of Chevron's two-step rule; there-
fore, it never reached the question of whether the FDA's regulation reflected a
"permissible construction." See Brown & Williamson, 153 F.3d at 161.
30. Brown & Williamson, 153 F.3d at 161-62.
[Vol. 25
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of the statute, the statutory scheme, legislative history, and other relevant
statutes. Beginning with the statute itself, the court found that tobacco
products are not drugs or devices under the Act." The FDCA requires
that a drug or device be "intended to affect the structure or any function
of the body."- 2 Tobacco certainly affects a structure or function of the
body and thus could possibly fit the definition, but tobacco manufacturers
do not market their products based on that characteristic. Tobacco's im-
pact on the body is thus not intended within the meaning of the Act."3
The court next considered the structure and purpose of the FDCA as
a wholeM Numerous provisions in the Act require the FDA to ensure the
safety of products. For example, the device provisions of the Act enable
the FDA to prohibit the sale of a device lacking a "reasonable assurance of
safety."35 The drug provisions require new drugs to be approved prior to
marketing for their safety.s6 Basically, if tobacco products were drugs or
devices, the Act would require the FDA to ensure their safety, but the FDA
contends the products are far from safe. 7 According to the court, "Con-
gress did not equip the FDA with tools appropriate for the regulation of
tobacco because it had no intention that the Act apply to tobacco prod-
31. See id. at 163-64.
32. See id. at 163 (citing 21 U.S.C. § 321(g)(1)(C) (1994)).
33. See Brown & Williamson, 153 F.3d at 163. Judge Hall, in his dissent, stated:
It strikes me as patently absurd to contend that cigarettes and smokeless
tobacco, products that are (under the assumed facts) actually designed to
exert powerful and quintessentially drug-like effects on the users, should
escape FDA regulation because the products are marketed as essential
accoutrements of a more exciting or more sophisticated lifestyle.
Id. at 178 (Hall, J., dissenting). In addition, the FDCA was deliberately drafted
broadly because Congress could not foresee every drug which the FDA would need
to regulate. See id. at 179 (Hall, J., dissenting). The district court deferred to the
agency's definition of "intended use" which considered foreseeable use, actual
consumer use, and knowledge of the manufacturers. See Coyne Beahm, Inc. v.
FDA, 966 F. Supp. 1374, 1391-92 (M.D.N.C. 1997), revd sub nom. Brown & William-
son Tobacco Corp. v. FDA, 153 F.3d 155 (4th Cir. 1998), and petition for cert. filed,
67 U.S.L.W. 3484 (U.S. Jan. 19, 1999) (No. 98-1152). The district court also up-
held the FDA's finding that tobacco products were combination products under
the FDCA and, with some misgivings, allowed the FDA to choose whether to regu-
late them as drugs or devices. See id. at 1392-97.
34. See Brown & Williamson, 153 F.3d at 163.
35. See id. at 164-66.
36. See id. The Fourth Circuit also discussed the labeling and cease-
distribution provisions of the Act. See id.
37. See id. at 164. The Fourth Circuit held that the agency improperly
weighed the risks inherent in removing tobacco from the market with tobacco's
negative impact on public health. See id. The agency should have weighed the
benefits of tobacco with the harm caused by using it. See id.
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The court's examination of legislative history includes the Agency's
prior interpretations of its enabling act. For sixty years, the FDA took the
position that "cigarettes marketed without therapeutic claims" were not
subject to its jurisdiction.'g Interestingly, the FDA refused to regulate ciga-
rettes even when specifically petitioned to do so.4° By its repeated inac-
tion, Congress acquiesced in the FDA's opinion that it lacked jurisdiction
over tobacco; Congress considered and rejected fifteen bills granting the
FDAjurisdiction over tobacco.
38. Id. at 167. A pair of commentators suggested a regulatory approach that
treats tobacco as a unique product: "Tobacco products cannot meet the 'safe and
effective' standard applied to drugs; such products are inherently toxic. Rather,
the overall standard should be no more poisonous (or dangerous) than necessary,
as is consistent with the recommendations of several major public health reports."
John Slade, M.D. &Jack E. Henningfield, Ph.D., Tobacco Regulation: Context and Is-
sues, 53 FOOD & DRUG L.J. Supp. 43, 65 (1998).
39. Brown & Williamson, 153 F.3d at 168. The court noted several specific
comments to this effect by the FDA between 1930 and 1989. See id. at 168-70. The
dissent stated that an agency may change its position, especially when new infor-
mation becomes available. See id. at 180 (Hall, J., dissenting). The FDA's knowl-
edge regarding the effect of tobacco on health has increased substantially since
the enactment of its enabling legislation. See id.; see also FDA's Petition for Writ of
Certiorari, FDA v. Brown & Williamson Tobacco Corp., (No. 98-1152), available in
Food & Drug Administration, Children & Tobacco: Court Opinions and Briefs (visited
Mar. 31, 1999) <http://www.fda.gov/opacom/campaigns/tobacco/tobcourL
html>. In its petition, the FDA wrote:
Prior to the present proceeding, FDA simply did not have clear and
compelling evidence that nicotine is extremely addictive, that consumers
use tobacco products because they are addicted to the products and want
to obtain their mood-altering and other effects, that manufacturers know
that consumers use tobacco products primarily for those reasons, and
that manufacturers have deliberately and carefully engineered tobacco
products to deliver pharmacologically active doses of nicotine.
Id.
40. See Brown & Williamson, 153 F.3d at 169. In finding that it did not have
authority to regulate tobacco, the FDA relied on FTC v. Liggett & Meyers Tobacco
Co., 108 F. Supp. 573, 577 (S.D.N.Y. 1952) (holding that tobacco is not a drug un-
der the Federal Trade Commission Act). The Liggett court applied a definition
similar to that in the federal Food, Drug and Cosmetics Act and distinguished be-
tween beneficial and non-adverse effects. See id. at 575. A claim of a non-adverse
effect, such as less irritation, does not qualify as a therapeutic claim. See id. A drug
has a therapeutic purpose. See id.
41. See Brown & Williamson, 153 F.3d at 170. The district court had found the
agency's prior position and these unenacted bills inadequate to suggest legislative
acquiescence. See Coyne Beahm, Inc. v. FDA, 966 F. Supp. 1374, 1382 (M.D.N.C.
1997), rev'd sub nom. Brown & Williamson Tobacco Corp. v. FDA, 153 F.3d 155
(4th Cir. 1998), and petition for cert. filed 67 U.S.L.W. 3484 (U.S. Jan 19, 1999) (No.
[Vol. 25
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In addition, Congress enacted other legislation specifically address-
ing labeling and advertising of tobacco products and access by minors-
the Federal Cigarette Labeling and Advertising Act,42 the Comprehensive
Smokeless Tobacco Act,45 and the Alcohol Drug Abuse and Mental Health
Administration Reorganization Act"-suggesting that it did not intend to
delegate to the FDA authority over tobacco.45
According to the Fourth Circuit, the goals of the Federal Cigarette
Labeling and Advertising Act ("FCLAA") are not consistent with FDA ju-
risdiction over tobacco for three reasons. First, the FCLAA states that a
national policy regarding tobacco must consider the impact of any legisla-
tion on the economy.4 The FDA's enabling act does not allow it to prom-
ulgate rules based on such broad societal concerns. Second, the FCLAA
allows the sale of tobacco products with certain labeling despite the
dangerousness of the products, but the FDA's enabling act does not per-
mit the sale of unsafe products.47 Third, a House committee considered
granting the FDAjurisdiction over tobacco, but the FCLAA, as passed by
Congress, did not include this provision. 48 The committee heard testi-
mony that allowing the FDA to regulate tobacco may lead to a complete
ban, a result not desired by Congress. 49
98-1152). It stressed that these bills were only discussed in committees and never
reported to the chambers. See id. at 1383. The court also distinguished between
acquiescence based on agency action and agency inaction, stating that the prece-
dent only supports acquiescence to action. See id. In addition, "[e]ven if Congress
acquiesced to FDA's assertion of lack ofjurisdiction, such acquiescence would not
necessarily connote Congress' opposition to FDA's assertion ofjurisdiction." Id. at
1384.
42. Pub. L. No. 89-92, 79 Stat. 283 (1965) (codified as amended at 15 U.S.C.
§§ 1331-1341 (1994)).
43. Pub. L. No. 99-952, 100 Stat. 30 (1986) (codified as amended at 15 U.S.C.
§§ 4401-4408 (1994)).
44. Pub. L. No. 102-321, 106 Stat. 323 (1992) (codified as amended at 42
U.S.C. §§ 300x-26 (1994)).
45. See Brown & Williamson, 153 F.3d at 171-76.
46. See id. at 172.
47. See id. at 172-73 (explaining that the House Committee on Interstate and
Foreign Commerce addressed this issue prior to passage of the FCLAA and that
the FCLLA requires warnings on package labels and advertisements).
48. See id. at 173. One commentator notes that Congress has given a regula-
tory role regarding tobacco to several agencies other than the FDA-the Federal
Trade Commission, Health and Human Services, Department of Agriculture, Bu-
reau of Alcohol, Tobacco and Firearms, and the Internal Revenue Service. See
John E. Jevicky, FDA's Regulation of Tobacco Products: A Hagrant Disregard of Congres-
sional Intent, 24 N. Ky. L. REv. 535, 542 (1997).
49. See Brown & Williamson, 153 F.3d at 172. Similarly, the goals of the
Smokeless Tobacco Act and Alcohol, Drug Abuse, and Mental Health Administra-
tion Reorganization Act suggest that the FDA does not have jurisdiction over to-
1999]
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In summary, the court in Brown & Williamson noted, "At its core, this
case is about who has the power to make this type of major policy deci-
sion .... [N]either federal agencies nor the courts can substitute their
policy judgments for those of Congress." ° One might conclude that the
court restrained the FDA from expanding its jurisdiction by a liberal in-
terpretation of its enabling act. On the other hand, the court rejected the
agency's analysis-based on the agency's decades of experience-for its
own. Brown & Williamson raises troubling questions about unaccountable
power; the public does not elect either agency heads or judges.-" In par-
ticular, the case raises these questions: When should a court defer to an
agency's change in position? What weight should courts give to Congress'
failure to act?
II. SEARCHING FOR CONGRESSIONAL INTENT: AN AGENCY'S CHANGE
IN POSITION
Courts tend to accept an agency's reversal of its policies because
agencies have to regulate in light of changing technology and public atti-
tudes.52 Courts must defer to an agency's interpretation of its enabling
legislation even if it varies. In Chevron U.S.A., Inc. v. Natural Resources De-
fense Council, Inc., 3 the U.S. Supreme Court stated:
The fact that the agency has from time to time changed its in-
bacco. See id. at 171-76. The Smokeless Tobacco Act provides a "detailed scheme"
which "evidences [Congress'] intent to retain authority over regulation of smoke-
less tobacco." See id. at 175. The Alcohol, Drug Abuse, and Mental Health Reor-
ganization Act focuses on state regulation in preventing minors from gaining ac-
cess to tobacco. See id.
50. Id. at 176.
51. See Kenneth Culp Davis & Richard J. Pierce, Jr., 3 ADMINIsTrTIVE LAw
TREA-nSE §§ 17.1, 17.4 (3d ed. 1994 & Supp. 1998) (noting that conferring broad
policymaking power on unelected bureaucrats raises serious questions and that
courts lack political legitimacy).
52. See, e.g., Rust v. Sullivan, 500 U.S. 173, 174 (1991) (noting that agencies
are allowed to adapt rules and policies to changes in circumstances); National
Muffler Dealers Ass'n, Inc. v. U.S., 440 U.S. 472, 485 (1979) ("We would be reluc-
tant to adopt the rigid view that an agency may not alter its interpretation in light
of administrative experience."); Committee for Effective Cellular Rules v. FCC, 53
F.3d 1309, 1317 (D.C. Cir. 1995) ("This flexibility is necessary to allow agencies...
to respond to rapidly changing '[tflechnological, commercial, and societal aspects
of the... industry' as they fulfill their delegated duties.") (quoting Rainbow
Broad. v. FCC, 949 F.2d 405,409 (D.C. Cir. 1991)); Peoples Fed. Sav. & Loan Ass'n
v. Commissioner, 948 F.2d 289, 302 (6th Cir. 1991) (stating that the IRS "should
have the freedom to alter its interpretations in light of its experience and percep-
tion of congressional movement").
53. 467 U.S. 837 (1984).
[Vol. 25
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terpretation of the term 'source' does not, as respondents ar-
gue, lead us to conclude that no deference should be accorded
the agency's interpretation of the statute. An initial agency in-
terpretation is not instantly carved in stone. On the contrary,
the agency, to engage in informed rulemaking, must consider
varying interpretations and the wisdom of its policy on a con-
tinuing basis. 4
In Rust v. Sullivan,55 the Supreme Court held that the U.S. Depart-
ment of Health and Human Services ("HHS") provided a reasoned basis
for its change of policy and thus acted within the authority granted by its
enabling act.6 HHS issued regulations requiring that clinics receiving
federal funds may not counsel patients regarding abortion or refer pa-
tients to abortion providers; engage in activities, such as lobbying, that
promote abortion; or operate a clinic which is not "physically and finan-
cially separate" from abortion-related activities.57 Prior to the promulga-
tion of these regulations, the agency allowed "nondirective counseling
and referral for abortion." ' The court held that, because the enabling act
was ambiguous9 and HHS gave a "reasoned analysis" of the basis for the
regulations, the agency acted within the bounds of its enabling statute.60
Rust v. Sullivan raised the question of when an agency explanation is suffi-
54. Id. at 863-64. But see Motor Vehicle Mfg. Ass'n v. State Farm Mut. Ins. Co.,
463 U.S. 29, 42 (1983) ("[A]n agency changing its course by rescinding a rule is
obligated to supply a reasoned analysis for the change beyond that which may be
required when an agency does not act in the first instance."). The Court held that
the agency had acted arbitrarily and capriciously because it failed to supply the
requisite "reasoned analysis" in the case. See id.
55. 500 U.S. 173 (1991).
56. See id. at 187. Four years earlier, the Court noted in a footnote to INS v.
Cardoza-Fonseca that "[a] n agency interpretation of a relevant provision which con-
flicts with the agency's earlier interpretation is 'entitled to considerably less defer-
ence' than a consistently held agency view." 480 U.S. 421, 447 n.30 (1987) (cita-
tion omitted). Some circuit courts have followed Cardoza-Fonseca. See, e.g., Wolpaw
v. Commissioner, 47 F.3d 787, 790 (6th Cir. 1995). Rust rejected this position. See
Rust, 500 U.S. at 185-87.
57. See Rust, 500 U.S. at 179-181.
58. See id. at 186.
59. Tide X, Section 1008 of the Public Health Service Act states, "None of the
funds appropriated under this subchapter shall be used in programs where abor-
tion is a method of family planning." Id. at 184. See also Pub. L. No. 57-242, 58
Stat. 682 (1994) (codified as amended at 42 U.S.C. § 300a-6 (1994)).
60. Id. at 187. The agency defended its position by stating that the new regu-
lations implement more effectively the intent of the enabling act, reflect client ex-
perience with the former policy, and, perhaps most interestingly, are in accord
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cient. How readily do or should courts accept rationalizations not backed
by solid evidence? When should an agency have the power to make
sweeping policy decisions through reinterpretation of its enabling act?
Following Rust, circuit courts have deferred to agency interpretations
of ambiguous enabling legislation. The Tenth Circuit, in Public Lands
Council v. Babbitt,6' upheld the Secretary of the Interior's reversal of a pol-
icy it had enforced for sixty-one years.62 The new regulation claimed title
for the government to range improvements such as fences, contrary to the
agency's prior position.63 The court noted that an agency need only pro-
vide a "reasoned analysis" when the enabling act is ambiguous.6 If the
statutory language is clear and "supports the new regulation," the court
can decide the issue without proceeding to step two of the Chevron analy-
sis. 6 The court accepted the agency's rationale based on efficient admini-
stration of its enabling acts, unified procedures between the Bureau of
Land Management and the Forest Service, and avoiding a confusing pro-
vision in the prior rule.6 Similarly, the Second Circuit in Himes v. Shalala6'
accepted an agency's change in position due to an amendment of one sec-
tion of its enabling statute.'
Rust v. Sullivan does not directly govern the Fourth Circuit's analysis
in Brown & Williamson. The dissent cited Rust and stated that the agency
had a reasoned basis for changing its policy in light of recent information
regarding the effect of smoking on public health.66 The majority, how-
ever, decided the case based on step one of the Chevron analysis: Congress
unambiguously withheld from the FDA the jurisdiction to regulate to-
61. 154 F.3d 1160 (10th Cir. 1998).
62. Id at 1178-79 n.13.
63. See id. at 1165-66. The Secretary of the Interior adopted other regulations
related to the management of grazing rights. See id. First, it redefined "grazing
preference" to include use of the land for purposes other than grazing. See id. at
1165. Second, the agency no longer required that the holder of a grazing prefer-
ence work in the "livestock business." See id. Third, the agency authorized conser-
vation use of grazing permit. See id. The Secretary implements the Taylor Grazing
Act of 1934, the Federal Lands Policy and Management Act of 1976, and the Pub-
lic Rangelands Improvement Act of 1978. See id. at 1163-64.
64. See id. at 1180.
65. See id. at 1179-80.
66. See id. at 1178.
67. 999 F.2d 684 (2d Cir. 1993).
68. See id. at 690. The court appeared particularly lenient in this case because
the agency's policy did not "represent an inexplicable, sharp break from the past."
Id.
69. See Brown & Williamson Tobacco Corp. v. FDA, 153 F.3d 155, 180 (4th




William Mitchell Law Review, Vol. 25, Iss. 2 [1999], Art. 1
http://open.mitchellhamline.edu/wmlr/vol25/iss2/1
FDA'S TOBACCO REGULATIONS
bacco. 70 The Fourth Circuit interpreted Chevron and Rust consistently with
the Tenth Circuit's interpretation in Public Lands Council.
If the Fourth Circuit found the enabling legislation ambiguous, it
would be compelled to defer to the FDA's change in position as long as
the FDA reasonably interpreted the statute.' By finding, however, that
Congress acquiesced to the FDA's statements regarding its lack ofjurisdic-
tion and thus intended that result, the court held the FDA to its initial po-
sition.7 The district court stated that acquiescence to the prior policy
does not suggest that Congress would oppose a change in the policy.
7 3
Congress could hardly logically support both a policy and its opposite, but
it could interpret an agency's discretion broadly enough to encompass
both possibilities. Congress may, moreover, appreciate the changes that
underlie an agency's reversal and thus alter its previous viewpoint. This
second possibility, however, should require an amendment of the agency's
enabling act.
III. SUBSEQUENT LEGISLATIVE HISTORY: A "POOR BEACON"? 74
The Fourth Circuit relied on subsequent legislative history in two
ways. First, because Congress failed to pass legislation overturning the
FDA's long-standing interpretation, the court found that Congress acqui-
esced to that position.75 Second, the court discerned the intent of the
Congress which enacted the FDCA through examining tobacco-specific
70. See id. at 161-62. The court reasoned:
It is only if the intent of Congress is ambiguous that we defer to a permis-
sible interpretation by the agency. And we note, with emphasis, that the
Supreme Court has stated that "[a] precondition to deference under
Chevron is a congressional delegation of administrative authority." Ac-
cordingly, no deference is due the FDA's construction of the Act unless it
is acting within the bounds of its congressionally-established authority. If
the court can ascertain Congress' intent on a particular question by ap-
plying the traditional rules of statutory construction, then it must give ef-
fect to that intent.... In fact, the Court instructs that the inquiry ends
with the statutory language when the language is unambiguous ....
Id. at 161-62 (citations omitted).
71. See id. at 161.
72. See id. at 170-71.
73. See Coyne Beahm, Inc. v. FDA, 966 F. Supp. 1374, 1383 (M.D.N.C. 1997),
rev'd sub nom. Brown & Williamson Tobacco Corp. v. FDA, 153 F.3d 155 (4th Cir.
1998), and petition for cert.filed 67 U.S.L.W. 3484 (U.S.Jan 19,1999) (No. 98-1152).
74. Zuber v. Allen, 396 U.S. 168, 185 (1969) ("Legislative silence is a poor
beacon to follow in discerning the proper statutory route.").
75. See Brown & Wiliamson, 153 F.3d at 171.
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legislation passed by later Congresses. 76 Both of these methods have re-
ceived substantial criticism.
"Subsequent legislative history" has been described as "an oxymo-
ron."77 Discerning the intent of one Congress through the actions of a
later Congress lacks reliability. Finding intent in Congress' failure to act
raises still more concerns. What is the message in the silence? Neverthe-
less, courts have found such history difficult to resist. On this issue, Pro-
fessor Tribe wrote:
Indeed, to decree that we must ignore legal silences altogether
is no more plausible than to command that we ignore the un-
covered parts of a canvas or the pauses in a sonata. As Susan
Sontag reminds us, '[t] o look at something which is "empty" is
still to be looking, still to be seeing. something-if only the
ghosts of one's own expectations . . . [.] Silence remains, ines-
capably, a form of speech.. . and an element in a dialogue.' 8
A. Legislative Acquiescence
"[W] hen an administrative interpretation of a statute has been called
to the legislature's attention, there is reason to regard the failure of the
legislature to act as evidence of the correctness of the interpretation.
"7
The Supreme Court has upheld legislative acquiescence in some circum-
stances. Bob Jones University v. United States0 addressed an IRS revenue rul-
ing which denied tax-exempt status to private schools that discriminate on
the basis of race.8' Congress rejected thirteen bills in twelve years which
would have overturned the ruling, and it amended section 501(c) (3) of
the IRS Code-the statutory section at issue-during that time period.
8 2
76. See id. at 178.
77. Strickland v. Commissioner, Me. Dep't of Human Servs., 48 F.3d 12, 18
(1st Cir. 1994).
78. LAURENCE H. TRIBE, CONSTrruTIONAL CHOICES 35-36 (1985) (citing The
Aesthetics of Silence, in STYLES OF RADIANCE WILL, 810, 811 (1969)).
79. Lanehart v. Homer, 818 F.2d 1574, 1579 (Fed. Cir. 1987) (citations omit-
ted).
80. 461 U.S. 574 (1983).
81. See id. at 578. "Based on the 'national policy to discourage racial dis-
crimination in education,' the IRS ruled that 'a private school not having a racially
nondiscriminatory policy as to students is not "charitable" within the common law
concepts reflected in sections 170 and 501(c) (3) of the Code.'" Id. at 579 (quot-
ing Rev. Rul. 71-447, 1971-2 C.B. 230, 231).
82. See id. at 599-600. Congress held "exhaustive hearings" beginning a
month after the publication of the revenue ruling. See id. at 600. This is no "ordi-
nary claim of legislative acquiescence." Id.
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The Supreme Court explained, "Few issues have been the subject of more
vigorous and widespread debate and discussion in and out of Congress
than those related to racial segregation in education."3
Two years later, the Supreme Court again found legislative acquies-
cence in the case United States v. Riverside Bayview Homes, Inc." Riverside
addressed the Corps of Engineer's interpretation of the Clean Air Act to
cover wetlands. 85 The Court noted that Congress amended the Clean Wa-
ter Act and debated the scope of wetlands protection under the Act in
816both houses. As the Act was finally passed, however, it did not limit the
Corps' jurisdiction over wetlands."
Bob Jones and Riverside both involve high-profile issues.88 Circuit
courts have hesitated to extend legislative acquiescence to topics receiving
less attention from Congress and the public.8 The D.C. Circuit, in fact,
has "consistently required express congressional approval of an administra-
tive interpretation if it is to be viewed as statutorily mandated."9 Legisla-
tive acquiescence forms just one of various tools of statutory construction;
83. Id. at 599. Compare Lanehart, 818 F.2d at 1579. The Lanehart court failed
to find legislative acquiescence where the issue--overtime pay for firefighters-
did not involve "considerable public controversy" and Congress lacked "prolonged
and acute awareness." Id. "Ordinarily, and quite appropriately, courts are slow to
attribute significance to the failure of Congress to act on particular legislation."
Id.
84. 474 U.S. 121 (1985).
85. See id. at 123. The Corps promulgated a rule defining "navigable waters"
as including "freshwater wetlands." Id. at 123-24. The Corps required a permit to
discharge fill into "waters of the United States." Id. at 123.
86. See id. at 136.
87. See id. at 136-37; see also NLRB v. Bell Aerospace Co., 416 U.S. 267, 282-84
(1974) (finding acquiescence where a Senate and House conference committee
report explained that Congress did not overturn the agency interpretation in re-
enacting legislation).
88. In addition to issues of public controversy, the Supreme Court has also
found acquiescence in cases of national security, "where congressional silence is
not to be equated with congressional disapproval." Haig v. Agee, 453 U.S. 280,
291 (1981).
89. See Peoples Fed. Savs. & Loan Ass'n v. Commissioner, 948 F.2d 289, 301
(6th Cir. 1991) (declining to find acquiescence where "the apparent degree of
scrutiny [by Congress] ... is zero"); Lanehart v. Homer, 818 F.2d 1574, 1579 (Fed.
Cir. 1987) (finding that the re-enactment doctrine does not apply where Congress
did not consider the specific issue at hand). Compare Michigan United Conserva-
tion Clubs v. Lujan, 949 F.2d 202, 210 (6th Cir. 1991) (finding that, where agency
delayed implementation of regulation to allow Congress to debate legislation,
Congress' failure to pass the legislation suggests ratification of the agency policy).
90. AFL-CIO v. Brock, 835 F.2d 912, 915 (D.C. Cir. 1987). "The district court
mistakenly relied on the familiar notion that Congress is presumed to be aware of
administrative interpretations of a statute or regulation when it adopts such lan-
guage in a statute." Id. at 916, n.6.
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its application seems to depend on the strength of the agency's position
overall. Courts rely on it in addition to other factors but do not tend to
give it considerable weight.9' Where the regulatory scheme is complex 92 or
the enabling act is clear, 93 courts are less likely to find acquiescence.
Circuit courts have criticized the re-enactment doctrine 94 for two
primary reasons: the negative impact on agency decision-making and lack
of reliability. One court explains, "The re-enactment doctrine, if rigidly
applied, becomes a trap for agencies.... [T]he misuse of this doctrine
may drastically curtail the scope and materially impair the flexibility of
administration actions." 95 Additionally, congressional inaction "may indi-
cate no more than the press of other business." 96 Inaction does not con-
91. See Strickland v. Commissioner, Me. Dept. of Human Servs., 48 F.3d 12,
19 (1st Cir. 1995) ("[T]he solitary reference to which appellants cling is too slen-
der a reed to be accorded controlling weight under the totality of the circum-
stances that obtain here."); Sweet Home Chapter v. Babbitt, 17 F.3d 1463, 1471
(D.C. Cir. 1994) ("We conclude that the acquiescence-by-reenactment rule is not
applicable to a situation where the regulations violate the original statutory lan-
guage and where Congress' decision not to amend the relevant statutory provi-
sions evidently stems from a belief that the provisions have been clear all along."),
rev'd, 515 U.S. 687 (1995); Michigan United, 949 F.2d at 210 ("[Wlhile post-
enactment developments cannot be accorded the weight of contemporary legisla-
tive history, and Congress' failure to disapprove a regulation is not dispositive of
congressional intent, the district court would be remiss if it ignored evidence that
implies congressional intent."); Massachusetts v. Secretary of Health & Human
Servs., 899 F.2d 53, 61 (1st Cir. 1990) ("Although appellees have stated a strong
case for congressional acquiescence, the ratification of one agency policy by Con-
gress does not preclude a change in that policy."), vacated ty Sullivan v. Massachu-
setts, 500 U.S. 949 (1991).
92. See Bell Fed. Sav. & Loan Ass'n v. Commissioner, 40 F.3d 224, 230 (7th
Cir. 1994) ("The regulations and statutes involved in this area are too complex for
us to venture to assume Congress's intent through its silence.").
93. See Mississippi Poultry Ass'n v. Madigan, 992 F.2d 1359, 1364-65 (5th Cir.
1993) (finding that Congress "is not required to respond to the Agency's disregard
of unequivocally expressed congressional intent by amending a statute that is both
clear and unambiguous on its face").
94. The re-enactment doctrine, closely related to legislative acquiescence,
provides that, if Congress re-enacts a provision with knowledge of an administra-
tive interpretation, and does not revise or repeal that interpretation, Congress has
acquiesced to the agency's position. See NLRB v. Bell Aerospace Co., 416 U.S. 267,
275 (1974) (citing Peoples Fed. Say. & Loan Ass'n v. Commissioner, 948 F.2d 289,
300-01 (6th Cir. 1991)). The Sixth Circuit stated, "[A]n important consideration
in the application of the re-enactment doctrine is 'the degree of scrutiny Congress
has devoted to the regulation during subsequent re-enactments of the statute.'"
Peoples, 948 F.2d at 301 (quoting National Muffler Dealers Ass'n v. United States,
440 U.S. 472, 477 (1979)).
95. Peoples, 948 F.2d at 302.
96. Sweet Home, 17 F.3d at 1469; see also Arnold Tours, Inc. v. Camp, 472 F.2d
427, 437 (1st Cir. 1972). That court observed:
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tain the same guaranties as action-debate in both houses, passage by
both houses, signature by the President."7 Legislative acquiescence allows
Congress to change the law without any political accountability. 9
Legislative acquiescence, moreover, upholds an agency's policy
choice and prevents a court from making that judgment; courts do not
generally use it to choose between two agency positions. The U.S. Su-
preme Court has explained:
We have held that "the construction of a statute by those
charged with its execution should be followed unless there are
compelling indications that it is wrong, especially when Con-
gress has refused to alter the administrative construction." Such
deference "is particularly appropriate where, as here, an
agency's interpretation involves issues of considerable public
controversy, and Congress has not acted to correct any misper-
ception of its statutory objectives.99
We cannot determine whether any committee or subcommittee of Con-
gress rejected, on the merits, the proposal to overturn the Comptroller's
ruling that national banks could engage in the travel agency business. It
may well have been that this ruling was simply viewed as an inconsequen-
tial aberration which would probably involve very few national banks and
hence was not deserving of legislative attention.
Id.
97. Cf Central Bank v. First Interstate Bank, 511 U.S. 164, 186 (1994) ("Con-
gressional inaction cannot amend a duly enacted statute."); Strickland v. Commis-
sioner, Me. Dep't of Human Servs., 48 F.3d 12, 18 (1st Cir. 1995) (noting that
Congress cannot amend a statute merely by inserting a proposed change in a uni-
cameral or bicameral report).
98. Professor Tribe explained:
[R]eading in the "silence of Congress" an indication of its "will" repre-
sents an attempt by judges to disclaim responsibility for altering the legal
landscape by passing the buck to Congress.... Worse still, Congress itself
may conspire in this buck-passing-for, having said nothing, its members
are free in turn to point right back to the courts when called upon to de-
fend what the courts claim that Congress has, by its silence, brought to
pass.
TRIBE, supra note 78, at 33-34. See generally DAVID SCHOENBROD, POWER WITHOUT
RESPONSIBILITY: How CONGRESS ABUSES THE PEOPLE THROUGH DELEGATION (1993)
(criticizing agency power).
99. CBS, Inc. v. FCC, 453 U.S. 367, 382 (1981) (citations omitted). In NLRB
v. Bell Aerospace Co., the Court also observed:
[A] court may accord great weight to the longstanding interpretation
placed on a statute by an agency charged with its administration. This is
especially so where Congress has re-enacted the statute without pertinent
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In contrast, the Fourth Circuit in Brown & Williamson relied on legis-
lative acquiescence to uphold a former FDA policy over a current FDA
policy.1 °° At least one circuit court has rejected the application of legisla-
tive acquiescence to challenge an agency's reversal. Before the U.S. Su-
preme Court decided Rust, the First Circuit addressed the same abortion
regulations.'O The First Circuit explained that "ratification of the previous
agency interpretation... would not indicate that the secretary's new pol-
icy exceeds his statutory authority."
0 2
B. Did Congress Acquiesce to the FDA's Prior Position on Tobacco?
After discussing Bob Jones University, the Fourth Circuit, in Brown v.
Williamson, stated, "We are of opinion that the matter before us presents
an equally strong case of legislative acquiescence. " °3 The district court,
however, had pointed out two flaws with that very conclusion. First,
though Congress has considered fifteen bills which would have granted
the FDA jurisdiction over tobacco, not one was debated on the House or
Senate floor.1'° Second, the Brown & Williamson case, unlike either Bob
Jones University or Riverside Bayview Homes, involves agency inaction-the




In Bob Jones University, the Supreme Court found acquiescence al-
though the thirteen bills seeking to overturn the IRS Revenue Ruling
change. In these circumstances, congressional failure to revise or repeal
the agency's interpretation is persuasive evidence that the interpretation
is the one intended by Congress.
416 U.S. 267, 274-75 (1974).
100. See Brown & Williamson Tobacco Corp. v. FDA, 153 F.3d 155, 170-71 (4th
Cir. 1998).
101. See Massachusetts v. Secretary of Health & Human Servs., 899 F.2d 53 (lst
Cir. 1990), vacated by Sullivan v. Massachusetts, 500 U.S. 949 (1991).
102. Id. at 61. See also Bell Fed. Savs. & Loan Ass'n v. Commissioner, 40 F.3d
224, 229 (7th Cir. 1994) ("Flexibility, too, is important as it constitutes one of the
basic precepts undergirding administrative law; to require an Act of Congress to
undo an agency's initial interpretation of a statute would largely eviscerate the use-
fulness of this organic body of law.").
103. 153 F.3d at 170.
104. See Coyne Beahm, Inc. v. FDA, 966 F. Supp. 1374, 1383 (M.D.N.C. 1996),
rev'd sub nom. Brown & Williamson Tobacco Corp. v. FDA, 153 F.3d 155 (4th Cir.
1998), and petition for cert. filed, 67 U.S.L.W. 3484 (U.S. Jan. 19, 1999) (No. 98-
1152). In United States v. Riverside Bayview Homes, 474 U.S. 121 (1985), the legisla-
tion at issue was reported out of committee. See id. at 121.
105. See Coyne, 966 F. Supp. at 1383.
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never left the committee. 0 6 In that case, however, numerous committee
meetings took place discussing that precise issue and Congress re-enacted
the relevant statutory section with no changes. 07 Brown & Williamson dis-
cussed several statements by the FDA to congressional committees be-
tween 1963 and 1989 denying its jurisdiction over tobacco. 10 8 Some of
these statements were made during hearings regarding tobacco legisla-
tion.1°9 The question remains, however, whether "few issues have been the
subject of more vigorous and widespread debate" than the FDA's jurisdic-
tion over tobacco and whether Congress has been "acutely aware" of the
issue."0 Congress has passed significant legislation on the issue of tobacco
regulation, but those bills reported out of committee do not specifically
address the FDA's jurisdiction."' Moreover, Congress did not amend the
FDCA to reflect its position on tobacco regulation.
The district court's second criticism also raises serious concerns. Ac-
cording to the Fourth Circuit, Congress acquiesced to the FDA's failure to
promulgate and enforce tobacco regulations."' This increases the level of
ambiguity as to Congress' intent. Courts have admitted the difficulties in-
herent in interpreting congressional silence;1 3 here Congress failed to act
based on the agency's failure to act.1
4
On the other hand, the FDA explained its judgment to Congress.
Congress perhaps acquiesced to the FDA's position as described in con-
gressional committee hearings. The Fourth Circuit does not address,
however, whether the doctrine of acquiescence should have equal force
with respect to a policy which did not receive any administrative process.115
If Congress had to dig through committee reports to discover the FDA's
position, it seems less likely that Congress has been "acutely aware" of the
issue. Moreover, committee reports themselves have been criticized as a
106. See Bob Jones Univ. v. U.S., 461 U.S. 574, 600 (1983).
107. See id.
108. See Brown & Williamson, 153 F.3d at 168-70.
109. See id.
110. Bob Jones Univ., 461 U.S. at 509.
111. See Brown & Williamson, 153 F.3d at 170.
112. See id. at 168-71.
113. See Bob Jones Univ., 461 U.S. at 600 ("Ordinarily, and quite appropriately,
courts are slow to attribute significance to the failure of Congress to act on particu-
lar legislation.").
114. The First Circuit distinguished between relying on acquiescence to show
an agency has authority and to prove an agency lacks authority. See Massachusetts
v. Secretary of Health & Human Servs., 899 F.2d 53, 61 (1st Cir. 1990).
115. Compare United States v. Riverside Bayview Homes, 474 U.S. 121, 138-39
(1985) (holding subsequent amendments to the Clean Water Act indicated that
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source of subsequent legislative history." 6
C. Subsequent Legislation
The Fourth Circuit reviewed tobacco-related legislation passed after
the FDCA to determine congressional intent regarding the FDCA. The
Supreme Court has routinely criticized this use of subsequent legislative
history: "[T] he views of a subsequent Congress form a hazardous basis for
inferring the intent of an earlier one.""7 The Court takes this position for
two reasons. First, "it is the function of the courts and not the Legislature,
much less a committee of one House of the Legislature, to say what an en-
acted statute means."" 8 Second, subsequent legislative history does not
form a reliable guide to intent. The Supreme Court stated, "Such history
does not bear strong indicia of reliability . . . because as time passes
memories fade and a person's perception of his earlier intention may
change."" 9 This history may also support more than one conclusion.1
2
0
Unenacted legislation 2 ' and committee reports 22 form particularly suspect
116. See Consumer Prod. Safety Comm'n v. GTE Sylvania, 447 U.S. 102, 118
(1980).
117. United States v. Price, 361 U.S. 304, 313 (1960); see also Central Bank v.
First Interstate Bank, 511 U.S. 164, 185 (1993) ("We have observed on more than
one occasion that the interpretation given by one Congress (or a committee or
Member thereof) to an earlier statute is of little assistance in discerning the mean-
ing of that statute.")
118. Pierce v. Underwood, 487 U.S. 552, 566 (1988); see also In re Conner
Home Sales Corp., 190 B.R. 255, 260 (E.D.N.C. 1995) (explaining that relying on
subsequent legislation history of an amendment would "in essence allow the legis-
lative history to be given retroactive application").
119. Consumer Prod. Safety, 447 U.S. at 118 n.13; see also Pennsylvania Med. Soc'y
v. Snider, 29 F.3d 886, 898 (3d Cir. 1994) ("Post-enactment legislative history is
not a reliable source for guidance.")
120. See Pension Benefit Guar. Corp. v. LTV Corp., 496 U.S. 633, 650 (1990);
see also Central Bank, 511 U.S. at 187 ("Several equally tenable inferences may be
drawn from [congressional] inaction.").
121. See Pension Benefit Guar., 496 U.S. at 650. One commentator noted:
[Jiustifying an interpretation of a prior enactment by pointing to what a
subsequent Congress did not enact seems incompatible with our constitu-
tional structure. Although silence contemporary with, or antecedent to,
the legislative speech one is construing adheres to and delimits that
speech-thus furnishing potentially relevant context-a later silence
shares no such boundary with that speech.
TRIBE, supra note 78, at 41 (footnote omitted). Compare these observations with
the earlier discussion of legislative acquiescence. See supra Part III.A. and accom-
panying notes.
122. See Consumer Prod. Safety, 447 U.S. at 118 (refusing to give weight to a
statement of the conference committee). Compare Archer-Daniels-Midland Co. v.
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The Court has, however, considered subsequent legislation in some
circumstances. In particular, where subsequent legislation makes clear
the intent of prior legislation, the Court has given it "great weight."1 23 In
Red Lion Broadcasting Co. v. FCC,124 the Court reviewed an FCC regulation
involving the "fairness doctrine"-the requirement that broadcasters
cover both sides of an issue. 25 In particular, the regulation required that
individuals have an opportunity to respond to negative publicity. 26 Con-
gress had amended the FCC's enabling statute, noting the "obligation im-
posed upon [broadcasters] under this Act... to afford reasonable oppor-
tunity for the discussion of conflicting views on issues of public
importance." 7
The broad policies which the Fourth Circuit in Brown & Williamson
discerns from the Federal Cigarette Labeling and Advertising Act differ
significantly from the clear message sent in Red Lion.2 s The tobacco legis-
lation does not mention the FDA's jurisdiction. Rather, the Fourth Cir-
cuit found that its purposes-regulation based on economic policy and
continued legality of tobacco-precluded regulation by the FDA.'
2 9
Moreover, Red Lion, unlike Brown & Williamson, addressed the amend-
ment of the agency's enabling act.1 s Congress makes a stronger statement
when it amends the legislation which empowers the agency.
The Fourth Circuit also noted that a congressional committee con-
sidered a role for the FDA in tobacco regulation.'' As enacted, the
152FCLAA did not contain this provision . The court stated that this com-
mittee report shed light on Congress's intent in enacting the FDCA. 3
U.S., 37 F.3d 321, 324 (7th Cir. 1994) (finding that "the slogan that Congress votes
on the bill and not on the report strikes us as pretty empty").
123. Red Lion Broad. Co. v. FCC, 395 U.S. 367, 380-81 (1969).
124. 395 U.S. 367 (1969).
125. See id. at 369.
126. See id. at 369-70.
127. Id. at 380.
128. See FDA's Petition for Writ of Certiorari, FDA v. Brown & Williamson To-
bacco Corp., (No. 98-1152), available in Food & Drug Administration, Children &
Tobacco: Court Opinions and Briefs (visited Mar. 31, 1999) <http://www.fda.
gov/opacom/campaigns/tobacco/tobcourt.html> (explaining that the statutes
discussed by the Fourth Circuit "address narrow issues" and do not exclude the
FDA from regulating tobacco).
129. Brown & Williamson Tobacco Corp. v. FDA, 153 F.3d 155, 172-73 (4th
Cir. 1998).
130. See Red Lion, 395 U.S. at 380-81.
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IV. SCOPE OF REVIEW: "How CLEAR IS CLEAR?"
13 5
Chevron, U.S.A., Inc. v. Natural Resources Defense Council, Inc. 36 set forth
the standard of review for an agency's interpretation of its enabling act:
When a court reviews an agency's construction of the statute
which it administers, it is confronted with two questions. First,
always, is the question whether Congress has directly spoken to
the precise question at issue. If the intent of Congress is clear,
that is the end of the matter; for the court, as well as the agency,
must give effect to the unambiguously expressed intent of Con-
gress. If, however, the court determines Congress has not di-
rectly addressed the precise question at issue, the court does not
simply impose its own construction on the statute, as would be
necessary in the absence of an administrative interpretation.
Rather, if the statute is silent or ambiguous with respect to the
specific issue, the question for the court is whether the agency's
answer is based on a permissible construction of the statute.3 7
134. See Consumer Prod. Safety Comm'n v. GTE Sylvania, 447 U.S. 102, 118
(1980). The FDA's enabling act, the FDCA, was passed in 1938. See Act of 1938,
ch. 675, 52 Stat. 140 (1938) (codified as amended at U.S.C. §§ 301-394 (1994)).
The Federal Cigarette Labeling and Advertising Act was enacted in 1965. See Pub.
L. No. 89-92, 79 Stat. 283 (1965) (codified as amended at 15 U.S.C. §§ 1331-1341
(1994)). The FDA cited the 1976 Medical Device Act, an amendment to the
FDCA, in asserting jurisdiction. See Coyne Beahm, Inc. v. FDA, 966 F. Supp. 1374,
1396 & 1396 n.18 (M.D.N.C. 1997), rev'd sub nom. Brown & Williamson Tobacco
Corp. v. FDA, 153 F.3d 155 (4th Cir. 1998), and petition for cert. filed, 67 U.S.L.W.
3484 (U.S. Jan. 19, 1999) (No. 98-1152). This pattern could be construed as ad-
dressing former legislative history. This would seem, however, to raise similar is-
sues. Looking to one Congress for the intent of another is always problematic. See
Western Fuels-Utah, Inc. v. Lujan, 895 F.2d 780, 786-87 n.10 (D.C. Cir. 1990).
135. Antonin Scalia, Judicial Deference To Administrative Interpretations of Law,
1989 DUKE L.J. 511, 520. Justice Scalia wrote:
Here, of course, is the chink in Chevron's armor-the ambiguity that
prevents it from being an absolutely clear guide to future judicial deci-
sions (though still a better one than what it supplanted). How clear is
clear? It is here, if Chevron is not abandoned, that the future battles over
acceptance of agency interpretations of law will be fought.
Id. at 520-21.
136. 467 U.S. 837 (1984).
137. Id. at 842-43 (footnotes omitted).
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This has been described as the "Chevron two-step" analysis.' 3 Chevron
defers to the agency interpretation of an ambiguous issue because the
agency, not the court, shoutd make policy judgments." 9 Two administra-
tive law experts explain, "When Congress enacts a statute to be adminis-
tered by an agency, it has delegated to the agency resolution of all policy
disputes that arise under that statute that Congress did not itself re-
solve. ,,
Commentators have questioned whether Chevron deference should
apply when an agency interprets the scope of its own power:
Where the agency is to make policy itself, its power must be
dominant. But where the agency derives the policy from some
other source, it must do so correctly. It is the courts' job to as-
sure that it does so and hence courts are given dominance of in-
terpretations of law, or derived policy. In the absence of such
judicial power, the bureaucracy would be free to act in the
derogation of the power properly exercised by these other insti-
tutions, particularly the legislatures.1
4 '
138. DAvis & PIERCE, supra note 51, § 3.2.
139. The Court wrote:
Judges are not experts in the field, and are not part of either political
branch of the Government. Courts must, in some cases, reconcile com-
peting political interests, but not on the basis of the judges' personal pol-
icy preferences. In contrast, an agency to which Congress has delegated
policy-making responsibilities may, within the limits of that delegation,
properly rely upon the incumbent administration's views of wise policy to
inform itsjudgments. While agencies are not directly accountable to the
people, the Chief Executive is, and it is entirely appropriate for this po-
litical branch of the Government to make such policy choices-resolving
the competing interests which Congress itself either inadvertently did not
resolve, or intentionally left to be resolved by the agency charged with
the administration of the statute in light of everyday realities.
When a challenge to an agency construction of a statutory provision,
fairly conceptualized, really centers on the wisdom of the agency's policy,
rather than whether it is a reasonable choice within a gap left open by
Congress, the challenge must fail. In such a case, federal judges-who
have no constituency-have a duty to respect legitimate policy choices
made by those who do. The responsibilities for assessing the wisdom of
such policy choices and resolving the struggle between competing views
of the public interest are not judicial ones: "Our constitution vests such
responsibilities in the political branches."
Chevron, 467 U.S. at 865-66.
140. DAvIs& PIERCE, supra note 51, § 3.3, at 114.
141. CHARLEs H. KOCH, JR., ADMINISTRATIVE LAw AND PRACTICE § 12.32, at 251
1999]
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The Supreme Court has provided some support for this approach.
In Adams Fruit Co. v. Barrett,142 the Court noted, "Although agency deter-
minations within the scope of delegated authority are entitled to defer-
ence, it is fundamental 'that an agency may not bootstrap itself into an
area in which it has no jurisdiction. "'143 Separating policy-making deci-
sions from non-policy-making decisions does not, however, seem intuitive.
In the facts of Brown & Williamson, for example, the FDA had broadened
itsjurisdiction through interpretation of its enabling legislation, but it also
made a policy judgment based on its expertise and empirical data regard-
ing the effect of tobacco on public health.
Chevron states that courts need only defer to agencies acting "within
the limits of [their] delegation,"'" which seems to suggest that a court
consider the limits of agency power as a part of step one. If, however,
those limits are not clear, the court must defer to an agency's reasonable
interpretation. This marks a difference between the Chevron approach
and the more independent review of Adams Fruit, as described above.
Buried in a footnote in Chevron is this instruction: "If a court, employ-
ing traditional tools of statutory construction, ascertains that Congress had an
intention on the precise question at issue, that intention is the law and
must be given effect."'" Chevron does not include a definition of these
traditional tools, and the Supreme Court has not made a definitive state-
ment on this issue. And yet, how the Supreme Court and circuit courts
define the traditional tools impacts administrative power,'" because courts
(1997). Agencies are far better equipped than courts to make policy decisions due
to their expertise and procedural possibilities. See id. § 12.31 [33, at 241. Cf Scalia,
supra note 135, at 516-17. Scalia concludes that Chevron, even if not a "100% accu-
rate estimation of modem congressional intent," clarifies the law by imposing a
consistent rule of deference to agency decision-making. Id. "Congress now knows
that the ambiguity it creates, whether intentionally or unintentionally, will be re-
solved, within the bounds of permissible interpretation, not by the courts but by a
particular agency, whose policy biases will ordinarily be known." Id.
142. 494 U.S. 638 (1990).
143. Id. at 650 (citation omitted); see also Hi-craft Clothing Co. v. NLRB, 660
F.2d 910, 916 (3d Cir. 1981) ("The more intense scrutiny that is appropriate when
the agency interprets its own authority may be grounded in the unspoken premise
that government agencies have a tendency to swell, not shrink, and are likely to
have an expansive view of their mission.").
144. Chevron, 467 U.S. at 865.
145. Id. at 843 n.9 (emphasis added).
146. DAVIS & PiERcE, supra note 51, § 3.6. The authors noted:
If reviewing courts are free to use any combination of the "traditional
tools of statutory construction" they choose in the process of applying
Chevron step one, few if any cases will reach Chevron step two. It is the
[Vol. 25
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sift administrative interpretations through step one of Chevron. Interpre-
tations which survive this first step will generally prevail on review. Inter-
pretations remaining in the strainer of step one review will be discarded.
Justice Scalia has attempted to restrict the scope of Chevron step one.
In a dissenting opinion to INS v. Cardoza-Fonseca,14 he stated:
The Court first implies that courts may substitute their interpre-
tation of a statute for that of an agency whenever, " [e] mploying
traditional tools of statutory construction," they are able to
reach a conclusion as to the proper interpretation of the statute.
But this approach would make deference a doctrine of despera-
tion, authorizing courts to defer only if they would otherwise be
unable to construe the enactment at issue.4
Justice Scalia also explained, "If Chevron is to have any meaning, then,
congressional intent must be regarded as 'ambiguous' not just when no
interpretation is even marginally better than any other, but rather when
two or more reasonable, though not necessarily equally valid, interpreta-
tions exist."'
4 9
The Supreme Court has not reached agreement as to the scope of
the "traditional tools."' Advocates of the plain meaning rule would limit
step one review to the language of the statute.'-' On the other hand, some
justices favor a broader review, including legislative history.'5 2  Circuit
courts, though they tend to defer more to agency interpretations,5 5 have
split on this issue.1
54
very indeterminacy of the "traditional tools" that gives judges the discre-
tion to make policy decisions through the process of statutory construc-
tion.
Id. at 129-30.
147. 480 U.S. 421 (1987).
148. Id. at 454.
149. Scalia, supra note 135, at 520.
150. DAvis & PIERCE, supra note 51, § 3.6, at 126-27.
151. See Public Citizen v. U.S. Dep't of Justice, 491 U.S. 440, 469 (1989) (Ken-
nedy, J., concurring) ("There is a ready starting point, which ought to serve also as
a sufficient stopping point, for this kind of analysis: the plain language of the stat-
ute.").
152. See Atkins v. Rivera, 477 U.S. 154, 166 n.10 (1986) (Blackmun, J.) (con-
sidering subsequent legislative history as a part of step one review).
153. DAvIs & PIERCE, supra note 51, § 3.6, at 88 (Supp. 1998).
154. See, e.g., Kofa v. INS, 60 F.3d 1084, 1088 (4th Cir. 1995) ("If the statute is
silent or ambiguous on the question, we next turn to the agency's interpreta-
tion."); Arkansas AFL-CIO v. FCC, 11 F.3d 1430, 1439 (8th Cir. 1993) (considering
legislative history as a part of step one); Security Bank Minn. v. Commissioner, 994
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V. CONCLUSION
The court in Brown & Williamson engaged in a detailed discussion of
subsequent legislative history as a part of Chevron step one review. As dis-
cussed above, another circuit may have interpreted step one more nar-
rowly and perhaps reached a different result. The case demonstrates the
uncertainty inherent in the Chevron test.
Leaving "traditional tools" undefined poses two dangers. First, vari-
ous circuit courts take differing views leading to inconsistent results. Sec-
ond, the distinction between review and policy-making becomes less clear.
In the gray area of step one, courts may impose their own policy through
overly-thorough or overly-creative interpretations of statutory language.
1 5
1
Thus, the premise underlying Chevron-that agencies, not courts, should
make policy-loses force. On the other hand, allowing judges to choose
among a variety of possible tools gives them the flexibility to consider the
strength of the particular evidence in the case. Judges may then tailor
their use of traditional tools to each case.
The Supreme Court should address this issue. In considering the
various traditional tools, the Court may want to evaluate the reliability of
each tool as a method of discerning congressional intent. As discussed in
Part III above, subsequent legislative history has received substantial criti-
cism related to reliability.15 6 Its place in the Chevron test seems dubious.
Despite the Fourth Circuit's reliance on subsequent legislative history
in Brown & Williamson, it is unclear to what extent that history influenced
its ultimate decision. The opinion includes a compelling discussion of
why the FDA's assertion of jurisdiction over tobacco violates the structure
and purpose of the FDCA. The crux of the problem is that the FDCA re-
F.2d 432, 436, 441 (8th Cir. 1993) (including legislative history but not subsequent
legislative history in step one); Western Fuels-Utah, Inc. v. Lujan, 895 F.2d 780,
784, 786 (D.C. Cir. 1990) (employing traditional tools including legislative history
but finding subsequent legislative history unreliable); Massachusetts v. Secretary of
Health & Human Servs., 899 F.2d 53, 58 (1st Cir. 1990) (stating factors in step one
include subsequent legislative history), rev'd, Rust v. Sullivan, 500 U.S. 173 (1991);
Bridgestone/Firestone, Inc. v. Pension Benefit Guar. Corp., 892 F.2d. 105, 110 n.5
(D.C. Cir. 1989) ("[T]he pronouncements of a subsequent Congress, here 13
years after the passage of ERISA, are notoriously unreliable indicators of the intent
of Congress at the time of passage, and we give very little weight to such revisionist
legislative history."); ACLU v. FCC, 823 F.2d 1554, 1568 (D.C. Cir. 1987) (holding
legislative history may be considered where necessary but not to contradict "plain
meaning" of statute); Almendarez v. Barrett-Fisher Co., 762 F.2d 1275, 1278 (5th
Cir. 1985) (finding legislative history useful in some circumstances to determine
congressional intent).
155. See DAvis& PIERCE, supra note 51, § 3.6 (Supp. 1998).
156. See supra Part II and accompanying notes.
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quires an assurance of safety which the FDA, bound by jurisdictional limi-
tations, cannot provide in the case of tobacco. In other words, the Fourth
Circuit may not have required the discussion of subsequent tobacco legis-
lation to tip the balance of evidence against the FDA.
Though Brown & Williamson raises troubling issues of judicial inter-
ference with agency policy-making, it also addresses agency interference
with legislative policy-making. The FDA gathered an impressive set of sta-
tistics demonstrating that tobacco is killing Americans.' Perhaps its regu-
lations are the solution, but Congress must first grant the FDA the author-
ity to implement them. The FDA appears to have modeled its regulations
on a bill in Congress which failed to pass. Thus, not only did the agency
arguably exceed the scope of its enabling legislation, it promulgated a pol-
icy rejected by Congress. When federal agencies like the FDA choose
their own role outside of the authority delegated to them by Congress, our
government becomes less representative and its branches less distinct.
On January 19, 1999, the Justice Department filed a petition for cer-
tiorari with the U.S. Supreme Court. 9 The FDA still has a hard fight
ahead of it, and the tobacco industry may win this round.
Jill Schlick
157. See supra note 2 and accompanying text.
158. See supra note 5 and accompanying text.
159. See Brown & Williamson Tobacco Corp. v. FDA, 153 F.3d 155 (4th Cir.
1998), and petition for cert. filed, 67 U.S.L.W. 3484 (U.S. Jan. 19, 1999) (No. 98-
1152). The petition has stayed the Fourth Circuit's decision, so the tobacco regu-
lations, meanwhile, remain in effect. See id.
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